Critical Limb Ischemia - Pipeline Review, H1 2017

Size: px
Start display at page:

Download "Critical Limb Ischemia - Pipeline Review, H1 2017"

Transcription

1 Critical Limb Ischemia - Pipeline Review, H1 2017

2 Critical Limb Ischemia - Pipeline Review, H BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or 2

3 Critical Limb Ischemia - Pipeline Review, H Critical Limb Ischemia - Pipeline Review, H Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2017, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape. Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 12, 4 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular). 3

4 - The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Additional Details Publisher : Global Markets Direct Reference : GMDHC9300IDB Number of Pages : 126 Report Format : PDF Publisher Information : 4

5 5

6 Table Of Contents for Critical Limb Ischemia - Pipeline Review, H [Report Updated: ] Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageCritical Limb Ischemia - OverviewCritical Limb Ischemia - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesCritical Limb Ischemia - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeCritical Limb Ischemia - Companies Involved in Therapeutics DevelopmentAnGes MG Incapceth Biopharma GmbHAthersys IncBiogenCell LtdCaladrius Biosciences IncCynata Therapeutics LtdHemostemix LtdHistocell SLID Pharma Co LtdIntegene International Holdings LLCJuventas Therapeutics IncKasiak Research Pvt LtdKowa Company LtdNeurofx IncPharmicell Co LtdPluristem Therapeutics IncReNeuron Group PlcSymic Biomedical IncTikoMed ABU.S. Stem Cell IncVericel CorpVESSL Therapeutics LtdViroMed Co LtdCritical Limb Ischemia - Drug ProfilesACP-01 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAdipoCell - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAlecmestencel-T - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressASCT-01 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressbeperminogene perplasmid - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBGC Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBiologic to Activate FGF2 for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCellgram-CLI - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCLBS-12 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDVC Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressGene Therapy for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressHC Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressixmyelocel-T - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressJVS Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMultiGeneAngio - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNFx Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNK-104 NP - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPF Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPLX-PAD - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressProtein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRefacell-CLI - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRejuveinix - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressReN Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSB Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Cardiovacular Diseases - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTM Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTXA Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressVM Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCritical Limb Ischemia - Dormant ProjectsCritical Limb Ischemia - Discontinued ProductsCritical Limb Ischemia - Product Development MilestonesFeatured News & Press ReleasesJan 17, 2017: Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing ApprovalJan 10, 2017: Pluristem's Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDANov 01, 2016: Pluristem s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory AgencyOct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in CanadaSep 08, 2016: Pluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a Multinational Conference on Vascular MedicineAug 09, 2016: Pluristem s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe s Horizon 2020 ProgramAug 02, 2016: Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb IschemiaJul 27, 2016: Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip FractureJun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb IschemiaApr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los AngelesApr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb IschemiaJan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical 6

7 StudyDec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United StatesDec 21, 2015: Pluristem Reaches Agreement with Japan s PMDA on Protocol for Final Trial Targeting Market Entry via Accelerated PathwayOct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the MesaAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer 7

8 How to Buy... Critical Limb Ischemia - Pipeline Review, H [Report Updated: ] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2000 Single User Price $4000 Site License Price $6000 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 8

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and

More information

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

Median Kliniken GmbH & Co. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Median Kliniken GmbH & Co. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Median Kliniken GmbH & Co. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Median Kliniken GmbH & Co. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Glenmark Pharmaceuticals Inc., USA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Glenmark Pharmaceuticals Inc., USA - Pharmaceuticals & Healthcare - Deals and Alliances Profile Glenmark Pharmaceuticals Inc., USA - Pharmaceuticals & Healthcare - Deals and Alliances Profile Glenmark Pharmaceuticals Inc., USA - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited

More information

Compression Therapy - Medical Devices Pipeline Assessment, 2017

Compression Therapy - Medical Devices Pipeline Assessment, 2017 Compression Therapy - Medical Devices Pipeline Assessment, 2017 Compression Therapy - Medical Devices Pipeline Assessment, 2017 BioPortfolio has been marketing business and market research reports from

More information

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market

More information

Phone: +44 (0) or BioPortfolio Limited

Phone: +44 (0) or   BioPortfolio Limited Global Laser Holographic Display Market by Product (Medical Scanners, Digital Signage, Kiosk, Notebook), by Application (Medical, Commercial, Industrial, Defense, Consumer Electronics), by Geography -

More information

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

McCain Foods Limited, Inc. - Strategic SWOT Analysis Review

McCain Foods Limited, Inc. - Strategic SWOT Analysis Review McCain Foods Limited, Inc. - Strategic SWOT Analysis Review McCain Foods Limited, Inc. - Strategic SWOT Analysis Review Sector Publishing Intelligence Limited (SPi) has been marketing business and market

More information

Gap, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Gap, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Gap, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Gap, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Sector Publishing Intelligence

More information

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Surgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing

Surgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing Surgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing Devices), and Sutures (Sutures by Type (Absorbable & Non-Absorbable),

More information

Kohler Co. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Kohler Co. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Kohler Co. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Kohler Co. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Sector Publishing Intelligence

More information

Vorwerk and Co. KG - Strategy, SWOT and Corporate Finance Report

Vorwerk and Co. KG - Strategy, SWOT and Corporate Finance Report Vorwerk and Co. KG - Strategy, SWOT and Corporate Finance Report Vorwerk and Co. KG - Strategy, SWOT and Corporate Finance Report The Business Research Store is run by Sector Publishing Intelligence Ltd.

More information

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector

More information

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Mindray Medical International Limited (MR) - Medical Equipment - Deals and Alliances Profile

Mindray Medical International Limited (MR) - Medical Equipment - Deals and Alliances Profile Mindray Medical International Limited (MR) - Medical Equipment - Deals and Alliances Profile Mindray Medical International Limited (MR) - Medical Equipment - Deals and Alliances Profile BioPortfolio has

More information

Maruti Suzuki India Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Maruti Suzuki India Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Maruti Suzuki India Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Maruti Suzuki India Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment

More information

The Walt Disney Company - Strategy, SWOT and Corporate Finance Report

The Walt Disney Company - Strategy, SWOT and Corporate Finance Report The Walt Disney Company - Strategy, SWOT and Corporate Finance Report The Walt Disney Company - Strategy, SWOT and Corporate Finance Report The Business Research Store is run by Sector Publishing Intelligence

More information

Paramount Mining Corporation Limited (PCP) - Metals and Mining - Deals and Alliances Profile

Paramount Mining Corporation Limited (PCP) - Metals and Mining - Deals and Alliances Profile Paramount Mining Corporation Limited (PCP) - Metals and Mining - Deals and Alliances Profile Paramount Mining Corporation Limited (PCP) - Metals and Mining - Deals and Alliances Profile Sector Publishing

More information

Generics Series: Authorized Generics Analysis Stemming the Generics Tide

Generics Series: Authorized Generics Analysis Stemming the Generics Tide Generics Series: Authorized Generics Analysis Stemming the Generics Tide Report summary An overview of the authorized generics landscape, including drivers and resistors for both branded and generics players

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

United States Sterilization Equipment Market Outlook to 2021

United States Sterilization Equipment Market Outlook to 2021 United States Sterilization Equipment Market Outlook to 2021 United States Sterilization Equipment Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected

More information

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW Global Transcatheter Aortic Valve Replacement (TAVR) Market: Analysis By Type of Approach (Transfemoral and Transapical), By Region, By Country: Opportunities and Forecast (2017-2022) By Type of Approach-

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

International R&D and Technology Transfer Agreements Negotiations and Conflict Management

International R&D and Technology Transfer Agreements Negotiations and Conflict Management International R&D and Technology Transfer Agreements Negotiations and Conflict Management Dr. Claus-Joerg Ruetsch, Head Legal Diagnostics F. Hoffmann-La Roche Ltd Alicante March 11, 2011 Negotiations and

More information

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast,

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, Transparency Market Research Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 2018 Buy Now Request Sample Published Date: Mar 2013 Single User

More information

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your

More information

Innovation and the Changing Practice of Medicine

Innovation and the Changing Practice of Medicine Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis

More information

Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research

Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research UCLA Research: A Winning Environment $811M+ in research awards for FY2006 3,300

More information

Leader in Pharmaceutical Films

Leader in Pharmaceutical Films TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation

More information

peace of mind For from development to commercial supply

peace of mind For from development to commercial supply For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved. Dealdoc Acquisition agreement for Gambro Baxter International Gambro Dec 04 2012 Acquisition agreement for Gambro Companies: Baxter International Gambro Announcement date: Dec 04 2012 Deal value, US$m:

More information

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &

More information

Abraxis: Emergent Life Science & Pharmaceutical Company

Abraxis: Emergent Life Science & Pharmaceutical Company Abraxis: Emergent Life Science & Pharmaceutical Company Abraxis BioScience, Inc. Michael J. Brunelle, VP Acquisition & Development UGL Equis Mark Berman, Managing Director Brad Gross, Senior Vice President

More information

China Ophthalmic Hospital Industry Report, May 2013

China Ophthalmic Hospital Industry Report, May 2013 China Ophthalmic Hospital Industry Report, 2012-2015 May 2013 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight

More information

Top 50 Emerging Technologies & Growth Opportunities

Top 50 Emerging Technologies & Growth Opportunities Top 50 Emerging Technologies & Growth Opportunities Multi-billion Dollar Technologies Ready to Energize Industries and Transform our World THE VALUE PROPOSITION TechVision s annual Top 50 Emerging Technologies

More information

September 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board

September 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT

More information

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members

More information

Digital Health Startups A FirstWord ExpertViews Dossier Report

Digital Health Startups A FirstWord ExpertViews Dossier Report AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in

More information

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number

More information

State of Licensing 2011 Update

State of Licensing 2011 Update State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

Scripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011

Scripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011 Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic

More information

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships R&D Solutions for PHARMA & LIFE SCIENCES DRUG DISCOVERY & DEVELOPMENT Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships Summary For pharmaceutical companies to succeed, it is

More information

China: Managing the IP Lifecycle 2018/2019

China: Managing the IP Lifecycle 2018/2019 China: Managing the IP Lifecycle 2018/2019 Patenting strategies for R&D companies Vivien Chan & Co Anna Mae Koo and Flora Ho Patenting strategies for R&D companies By Anna Mae Koo and Flora Ho, Vivien

More information

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014 Sector insights The healthcare market is highly complex with global products delivered through local services and channels. The healthcare value chain is intricate, diverse and interdependent. It is a

More information

Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC

Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC Study overview Part 1: The Global Biomedical Industry: Understanding the

More information

Lupin Limited Annual Results FY12. Investor Presentation May being

Lupin Limited Annual Results FY12. Investor Presentation May being Lupin Limited Annual Results FY12 Investor Presentation May 2012 Vision: To be an innovation led transnational company Journey over the last decade 5th largest generics player in US Gross Revenues INR

More information

EXECUTIVE BRIEF. Technology Insights in CODING AND MARKING 2016

EXECUTIVE BRIEF. Technology Insights in CODING AND MARKING 2016 EXECUTIVE BRIEF Technology Insights in CODING AND MARKING 2016 Analyzing Technologies Landscape and Patent Strategies in the Global Coding and Marking Market Author : Alain Dunand January 4, 2017 We are

More information

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost

More information

Medical Device Usability Engineering. Product and Service Design Innovation Consultancy

Medical Device Usability Engineering. Product and Service Design Innovation Consultancy Medical Device Usability Engineering Product and Service Design Innovation Consultancy Delivering Meaningful Innovation PDD services Our integration of multiple disciplines means we offer a comprehensive

More information

For personal use only

For personal use only ASX ANNOUNCEMENT AGM PRESENTATION SYDNEY, Monday 21 November 2016: Cellmid Limited (ASX:CDY) provides the following presentation for the Annual General Meeting of the shareholders. End Contact: Maria Halasz,

More information

Intellectual Property Policy. DNDi POLICIES

Intellectual Property Policy. DNDi POLICIES Intellectual Property Policy DNDi POLICIES DNDi hereby adopts the following intellectual property (IP) policy: I. Preamble The mission of DNDi is to develop safe, effective and affordable new treatments

More information

2018 Chem- Pharma- Biotech Highlights on Patentability and Patent Infringement

2018 Chem- Pharma- Biotech Highlights on Patentability and Patent Infringement 2018 Chem- Pharma- Biotech Highlights on Patentability and Patent Infringement Barcelona, 6 February 2018 Madrid, 7 February 2018 Outlook As "Highlights" the organizers will be offering advanced patent

More information

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research Life Sciences Long Island 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research Suffolk County Stony Brook University serves as an integral part of the research corridor

More information

[ Feature ] JAIC has the largest number of domestic and overseas entitles among the Japanese venture capital companies. Flexing the Muscles of

[ Feature ] JAIC has the largest number of domestic and overseas entitles among the Japanese venture capital companies. Flexing the Muscles of Global Linkage Network JAIC has the largest number of domestic and overseas entitles among the Japanese venture capital companies. Flexing the Muscles of BioVentures in Japan and Beyond Mr Tsutomu Kanezaki

More information

USTGlobal. 3D Printing. Changing the Face of Healthcare

USTGlobal. 3D Printing. Changing the Face of Healthcare USTGlobal 3D Printing Changing the Face of Healthcare UST Global Inc, November 2017 Table of Contents Introduction 3 Challenges 3 Impact of 3D Printing 4 IT Solutions for 3D Printing 5 How UST Global Can

More information

Supporting Innovation through Regulation and Science

Supporting Innovation through Regulation and Science Supporting Innovation through Regulation and Science Larry O Dwyer, Scientific Affairs Manager PEARRL Regulatory Science Symposium 21 st June 2017, School of Pharmacy, UCC Overview of Presentation Drivers

More information

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical

More information

Making lives better every day. This is UCB

Making lives better every day. This is UCB Making lives better every day. This is UCB Kristof, living with axial spondyloarthritis Remi, UCB Inspired by patients. Driven by science. We have a shared ambition to transform the lives of people living

More information

Comprehensive Research Services

Comprehensive Research Services Comprehensive Research Services Scripps Health: At the Forefront of Clinical Research Scripps Health is a recognized leader in clinical research and has long been at the forefront of numerous medical breakthroughs.

More information

Draft Plan of Action Chair's Text Status 3 May 2008

Draft Plan of Action Chair's Text Status 3 May 2008 Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background

More information

Dr Graham Spittle CBE Chairman, The Technology Strategy Board Speech to The Foundation for Science and Technology, 23 rd November, 2011

Dr Graham Spittle CBE Chairman, The Technology Strategy Board Speech to The Foundation for Science and Technology, 23 rd November, 2011 Dr Graham Spittle CBE Chairman, The Technology Strategy Board Speech to The Foundation for Science and Technology, 23 rd November, 2011 Contribution of research and innovation to growth of the economy

More information

J.P. Morgan Healthcare Conference Summary Transcript

J.P. Morgan Healthcare Conference Summary Transcript J.P. Morgan Healthcare Conference Summary Transcript Good afternoon, everyone. I'm Shigeo Taniuchi. I'm President and COO of Santen Pharmaceutical. I joined Santen in 1996, and I became the President and

More information

executives are often viewed to better understand the merits of scientific over commercial solutions.

executives are often viewed to better understand the merits of scientific over commercial solutions. Key Findings The number of new technology transfer licensing agreements earned for every $1 billion of research expenditure has fallen from 115 to 109 between 2004 and. However, the rate of return for

More information

Study overview. The Global Biomedical Industry: Preserving U.S. Leadership

Study overview. The Global Biomedical Industry: Preserving U.S. Leadership Presentation for: Voluntary Health Leadership Conference February 9, 2012 Rancho Bernardo Inn San Diego, CA Ross DeVol Chief Research Officer Milken Institute Study overview Part 1: Understanding the Factors

More information

Endocrinology, Diabetes, & Lipid Clinic History Questionnaire Fill out in BLACK ink

Endocrinology, Diabetes, & Lipid Clinic History Questionnaire Fill out in BLACK ink Endocrinology, Diabetes, & Lipid Clinic History Questionnaire Fill out in BLACK ink Name: Date of Birth: Date: Race: GENDER: Male Female Height (inch): Weight (lbs) AGE: FAX#: E-mail: PHONE (Home): (Cell):

More information

Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo Dr. Axel Braun F. Hoffmann La Roche Ltd.

Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo Dr. Axel Braun F. Hoffmann La Roche Ltd. Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo 2011 Dr. Axel Braun F. Hoffmann La Roche Ltd. Content Roche Company Profile The IP Department Patent Filings Global Strategy Sales Overview IP

More information

EU s Innovative Medical Technology and EMA s Measures

EU s Innovative Medical Technology and EMA s Measures EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency

More information

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back.

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back. Renew-New PHARMA S NEW PHASE Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom They re back. Mergers & acquisitions, that is and in a big way. Wall Street and City

More information

AstraZeneca 2013 AGM

AstraZeneca 2013 AGM AstraZeneca 2013 AGM Chief Executive s Remarks 25 April 2013 Introduction Thank you, Leif. Ladies and gentlemen, good afternoon. I would like to add my own welcome to you this afternoon and thank you for

More information

2,500,000 Shares. Common Stock

2,500,000 Shares. Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-201841 Prospectus Supplement No. 15 to Prospectus dated February 26, 2015 2,500,000 Shares Common Stock This Prospectus Supplement No. 15

More information

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences

More information

COMPREHENSIVE COMPETITIVE INTELLIGENCE MONITORING IN REAL TIME

COMPREHENSIVE COMPETITIVE INTELLIGENCE MONITORING IN REAL TIME CASE STUDY COMPREHENSIVE COMPETITIVE INTELLIGENCE MONITORING IN REAL TIME Page 1 of 7 INTRODUCTION To remain competitive, Pharmaceutical companies must keep up to date with scientific research relevant

More information

Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use

Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use Rosmin Esmail MSc, CHE Director, Knowledge Translation Research, Analytics and Innovation Portfolio Alberta

More information

Digital Medical Device Innovation: A Prescription for Business and IT Success

Digital Medical Device Innovation: A Prescription for Business and IT Success 10 September 2018 Digital Medical Device Innovation: A Prescription for Business and IT Success A Digital Transformation is reshaping healthcare. New technology, mobility, and advancements in computing

More information

Presentation. March 2007

Presentation. March 2007 Presentation March 2007 1 Corporate Overview 2 Corporate Overview Leading provider of research-driven packaging solutions solely-focused on pharmaceutical industry Founded in 1994 and based in Pune, India

More information

Health & Social Care Industrial Innovation

Health & Social Care Industrial Innovation Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging

More information

Trends in Healthcare Investments and Exits 2018

Trends in Healthcare Investments and Exits 2018 Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview

More information

Announcement of the US Business Restructuring

Announcement of the US Business Restructuring August 15, 2018 Shin Nippon Biomedical Laboratories, Ltd. (The First Section of the Tokyo Stock Code Number: 2395) Representative: Chairman and President Ryoichi Nagata C o n t a c t : Senior Executive

More information

SHTG primary submission process

SHTG primary submission process Meeting date: 24 April 2014 Agenda item: 8 Paper number: SHTG 14-16 Title: Purpose: SHTG primary submission process FOR INFORMATION Background The purpose of this paper is to update SHTG members on developments

More information

Daryn A. Grossman. Proskauer.com. Partner. New York

Daryn A. Grossman. Proskauer.com. Partner. New York Contact Daryn A. Grossman Partner New York +1.212.969.3665 dgrossman@proskauer.com Daryn A. Grossman is co-chair of Proskauer s global Corporate Department. She serves as the head of the Life Sciences

More information

SPORTS MEDICINE: TECHNOLOGIES AND GLOBAL MARKETS

SPORTS MEDICINE: TECHNOLOGIES AND GLOBAL MARKETS SPORTS MEDICINE: TECHNOLOGIES AND GLOBAL MARKETS HLC183A March 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-061-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

Your Content Your Way

Your Content Your Way MY VIEW Your Content Your Way My View allows you to view only the topics you want to follow. Choose from a list of available topics, which are individualized for each publications, and design your own

More information